Insider · CIK 0001762611
Christopher Ray Aker
officer
Files at RGLS (Regulus Therapeutics Inc.). First filing Jan 15, 2025, latest Jan 15, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $55k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Regulus Therapeutics Inc. | $55k 43,635 shares | -47% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | UTender of shares Common Stock | -60,796 | - | - | 83,125 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Common Stock | -83,125 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -2,500 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -750 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -33,500 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -21,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -48,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -7,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -45,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -393,750 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -70,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -363,000 | - | - | 0 | Jun 27, 2025 |
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | DDisposition to issuer Stock Optionderivative | -487,500 | - | - | 0 | Jun 27, 2025 |
| Jan 30, 2025 | RGLS Regulus Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +487,500 | $0.00 | $0 | 487,500 | Jan 31, 2025 |
| Jan 13, 2025 | RGLS Regulus Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -38,547 | $1.26 | $49k | 54,634 | Jan 15, 2025 |
| Jan 14, 2025 | RGLS Regulus Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -5,088 | $1.26 | $6,427 | 49,546 | Jan 15, 2025 |
| Jan 9, 2025 | RGLS Regulus Therapeutics Inc. | AGrant or award Common Stock | +66,625 | $1.36 | $91k | 75,681 | Jan 10, 2025 |
| Jan 9, 2025 | RGLS Regulus Therapeutics Inc. | AGrant or award Common Stock | +17,500 | $1.30 | $23k | 93,181 | Jan 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.